A total of $343 million in private capital was invested in five key biotechnology/therapeutics initiatives for the week ending January 24.
The firms involved were some of the usual suspects with life sciences investors scrambling to help advance gene editing techniques and treatments for cancer and rare diseases.
Hedge fund firm Citadel’s Surveyor Capital participated in two of this past week’s deals, backing Verve Therapeutics and Vera Therapeutics. Set up in 2008, the firm is a global, multi-manager equities strategy and is one of Citadel’s three fundamental equities business.Continue Reading
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available. Research articles require an Annual sub.